Sunghoi Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sunghoi Hong has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Insik Hwang
School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul, Republic of Korea
12 shared publications- Kyung-Ah Choi
School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul 136-701, Republic of Korea; Department of Chemistry, College of Science, Korea University, Seoul 136-701, Republic of Korea
11 shared publications - Hyesun Jeong
School of Biosystem and Biomedical Science, College of Health Science, Korea University, Anam-dong, Seongbuk-gu, Seoul, Republic of Korea
8 shared publications - Hang-Soo Park
Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA
7 shared publications - Yeonho Choi
Korea University
6 shared publications Donghun Hyun
Department of Integrated Biomedical and Life Science, Korea University
5 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1899823
AQP4 antibody-induced astrocyte injury reshapes CNS immune architecture in a combined EAE–AQP4-IgG model of neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are inflammatory autoimmune diseases of the central nervous system (CNS) that share demyelinating features but differ fundamentally in pathogenesis. The discovery of neuromyelitis optica immunoglobulin G antibodies (NMO-IgG) that target aquaporin-4 (AQP4) established NMOSD as a distinct clinical entity, although the experimental platforms used to dissect the mechanistic basis of this disorder remain insufficiently defined. Thus, this study aimed to develop a combined EAE-AQP4-IgG model by intrathecally delivering patient-derived NMO-IgG and human complement into pre-immunized mice to compare the associated pathology with that of experimental autoimmune encephalomyelitis (EAE), a representative model of MS. Both models exhibited blood–brain barrier (BBB) disruption, reflected by altered ZO-1 and CD31 expression. Notably, glial fibrillary acidic protein (GFAP) was strongly upregulated in EAE, whereas in the combined EAE-AQP4-IgG model, GFAP was acutely lost, indicating antibody-mediated astrocyte destruction. Consistently, AQP4 expression was markedly reduced in combined EAE-AQP4-IgG model animals. Combined EAE-AQP4-IgG model mice also displayed more severe demyelination and inflammation, confirmed by Luxol Fast Blue and H&E staining, electron microscopy, and MBP/Iba1 immunostaining. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) further revealed distinct inflammatory signatures: CCL2 and BCL6 were elevated in EAE, whereas IL-6 , IL-17A , CXCL13 , and PRDM1 were strongly upregulated in combined EAE-AQP4-IgG model. These differences were consistently observed across the brain, spinal cord, and optic nerve, albeit with regional variation. These results suggest that AQP4-IgG-induced astrocyte injury may redirect the CNS-related inflammatory milieu, shifting the CCL2-dominant, repair-permissive EAE environment into an IL-6–CXCL13–PRDM1 axis-driven, B cell-amplifying, remyelination-inefficient state that closely resembles the immunopathological context of human NMOSD. This combined EAE-AQP4-IgG model provides a robust platform for mechanistic investigation and therapeutic development.
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1899823
Open AccessAQP4 antibody-induced astrocyte injury reshapes CNS immune architecture in a combined EAE–AQP4-IgG model of neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are inflammatory autoimmune diseases of the central nervous system (CNS) that share demyelinating features but differ fundamentally in pathogenesis. The discovery of neuromyelitis optica immunoglobulin G antibodies (NMO-IgG) that target aquaporin-4 (AQP4) established NMOSD as a distinct clinical entity, although the experimental platforms used to dissect the mechanistic basis of this disorder remain insufficiently defined. Thus, this study aimed to develop a combined EAE-AQP4-IgG model by intrathecally delivering patient-derived NMO-IgG and human complement into pre-immunized mice to compare the associated pathology with that of experimental autoimmune encephalomyelitis (EAE), a representative model of MS. Both models exhibited blood–brain barrier (BBB) disruption, reflected by altered ZO-1 and CD31 expression. Notably, glial fibrillary acidic protein (GFAP) was strongly upregulated in EAE, whereas in the combined EAE-AQP4-IgG model, GFAP was acutely lost, indicating antibody-mediated astrocyte destruction. Consistently, AQP4 expression was markedly reduced in combined EAE-AQP4-IgG model animals. Combined EAE-AQP4-IgG model mice also displayed more severe demyelination and inflammation, confirmed by Luxol Fast Blue and H&E staining, electron microscopy, and MBP/Iba1 immunostaining. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) further revealed distinct inflammatory signatures: CCL2 and BCL6 were elevated in EAE, whereas IL-6 , IL-17A , CXCL13 , and PRDM1 were strongly upregulated in combined EAE-AQP4-IgG model. These differences were consistently observed across the brain, spinal cord, and optic nerve, albeit with regional variation. These results suggest that AQP4-IgG-induced astrocyte injury may redirect the CNS-related inflammatory milieu, shifting the CCL2-dominant, repair-permissive EAE environment into an IL-6–CXCL13–PRDM1 axis-driven, B cell-amplifying, remyelination-inefficient state that closely resembles the immunopathological context of human NMOSD. This combined EAE-AQP4-IgG model provides a robust platform for mechanistic investigation and therapeutic development.
- Open Access
- 30 May 2025
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 43 (8)
Neural stem cell-derived extracellular vesicles alleviate inflammatory responses in a mouse model of atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by disrupted epidermal barrier function and excessive immune activation. Conventional treatments using corticosteroids and immunosuppressants provide only temporary relief and often induce adverse side effects, highlighting the need for novel, effective therapy. In this study, we investigated the therapeutic potential of neural stem cell-derived extracellular vesicles (NSC-EVs) derived from NSC-derived conditioned medium (NSC-CM) in modulating inflammatory responses in AD. In vitro experiments using human keratinocytes (HaCaT) and murine macrophages (RAW264.7) showed that both NSC-CM and NSC-EVs can significantly decrease the expression of proinflammatory cytokines and chemokines, inhibit the phosphorylation of NF-κB, and reduce inducible nitric oxide synthase. In addition, topical application of NSC-CM and NSC-EVs alleviated atopic symptoms, reduced mast cell infiltration, and improved skin barrier integrity in a 2,4-dinitrochlorobenzene-induced AD mouse model. Proteomic analysis identified key proteins related to immune regulation and extracellular matrix remodeling in NSC-EVs, indicating their active role in mitigating inflammation and tissue repair. Altogether, our results demonstrated the potent anti-inflammatory effects of NSC-EVs, highlighting their potential to be a novel and effective therapeutic option for AD and other inflammation-related diseases.
- 30 May 2025
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 43 (8)
Open AccessNeural stem cell-derived extracellular vesicles alleviate inflammatory responses in a mouse model of atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by disrupted epidermal barrier function and excessive immune activation. Conventional treatments using corticosteroids and immunosuppressants provide only temporary relief and often induce adverse side effects, highlighting the need for novel, effective therapy. In this study, we investigated the therapeutic potential of neural stem cell-derived extracellular vesicles (NSC-EVs) derived from NSC-derived conditioned medium (NSC-CM) in modulating inflammatory responses in AD. In vitro experiments using human keratinocytes (HaCaT) and murine macrophages (RAW264.7) showed that both NSC-CM and NSC-EVs can significantly decrease the expression of proinflammatory cytokines and chemokines, inhibit the phosphorylation of NF-κB, and reduce inducible nitric oxide synthase. In addition, topical application of NSC-CM and NSC-EVs alleviated atopic symptoms, reduced mast cell infiltration, and improved skin barrier integrity in a 2,4-dinitrochlorobenzene-induced AD mouse model. Proteomic analysis identified key proteins related to immune regulation and extracellular matrix remodeling in NSC-EVs, indicating their active role in mitigating inflammation and tissue repair. Altogether, our results demonstrated the potent anti-inflammatory effects of NSC-EVs, highlighting their potential to be a novel and effective therapeutic option for AD and other inflammation-related diseases.
- Open Access
- 22 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
GCC2 promotes non-small cell lung cancer progression by maintaining Golgi apparatus integrity and stimulating EGFR signaling pathways
Fundamental changes in intracellular processes, such as overactive growth signaling pathways, are common in carcinomas and are targets of many cancer therapeutics. GRIP and coiled-coil containing 2 (GCC2) is a trans-Golgi network (TGN) golgin maintaining Golgi apparatus structure and regulating vesicle transport. Here, we found an aberrant overexpression of GCC2 in non-small cell lung cancer (NSCLC) and conducted shRNA-mediated gene knockdown to investigate the role of GCC2 in NSCLC progression. shRNA-mediated GCC2 knockdown suppressed NSCLC cell growth, migration, stemness, and epithelial-mesenchymal transition (EMT) in vitro and tumor growth in vivo. In addition, GCC2 knockdown suppressed cancer cell exosome secretion and the oncogenic capacity of cancer cell-derived exosomes. Mechanistically, GCC2 inhibition decreased epidermal growth factor receptor (EGFR) expression and downstream growth and proliferation signaling. Furthermore, GCC2 inhibition compromised Golgi structural integrity in cancer cells, indicating a functional role of GCC2 in regulating intracellular trafficking and signaling to promote lung cancer progression. Together, these findings suggest GCC2 as a potential therapeutic target for the treatment of NSCLC.
- 22 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Open AccessGCC2 promotes non-small cell lung cancer progression by maintaining Golgi apparatus integrity and stimulating EGFR signaling pathways
Fundamental changes in intracellular processes, such as overactive growth signaling pathways, are common in carcinomas and are targets of many cancer therapeutics. GRIP and coiled-coil containing 2 (GCC2) is a trans-Golgi network (TGN) golgin maintaining Golgi apparatus structure and regulating vesicle transport. Here, we found an aberrant overexpression of GCC2 in non-small cell lung cancer (NSCLC) and conducted shRNA-mediated gene knockdown to investigate the role of GCC2 in NSCLC progression. shRNA-mediated GCC2 knockdown suppressed NSCLC cell growth, migration, stemness, and epithelial-mesenchymal transition (EMT) in vitro and tumor growth in vivo. In addition, GCC2 knockdown suppressed cancer cell exosome secretion and the oncogenic capacity of cancer cell-derived exosomes. Mechanistically, GCC2 inhibition decreased epidermal growth factor receptor (EGFR) expression and downstream growth and proliferation signaling. Furthermore, GCC2 inhibition compromised Golgi structural integrity in cancer cells, indicating a functional role of GCC2 in regulating intracellular trafficking and signaling to promote lung cancer progression. Together, these findings suggest GCC2 as a potential therapeutic target for the treatment of NSCLC.
- Open Access
- 26 June 2024
- Published by MDPI AG in Technologies
- Vol. 12 (7) , 95
Integrating Artificial Intelligence to Biomedical Science: New Applications for Innovative Stem Cell Research and Drug Development
Artificial intelligence (AI) is rapidly advancing, aiming to mimic human cognitive abilities, and is addressing complex medical challenges in the field of biological science. Over the past decade, AI has experienced exponential growth and proven its effectiveness in processing massive datasets and optimizing decision-making. The main content of this review paper emphasizes the active utilization of AI in the field of stem cells. Stem cell therapies use diverse stem cells for drug development, disease modeling, and medical treatment research. However, cultivating and differentiating stem cells, along with demonstrating cell efficacy, require significant time and labor. In this review paper, convolutional neural networks (CNNs) are widely used to overcome these limitations by analyzing stem cell images, predicting cell types and differentiation efficiency, and enhancing therapeutic outcomes. In the biomedical sciences field, AI algorithms are used to automatically screen large compound databases, identify potential molecular structures and characteristics, and evaluate the efficacy and safety of candidate drugs for specific diseases. Also, AI aids in predicting disease occurrence by analyzing patients’ genetic data, medical images, and physiological signals, facilitating early diagnosis. The stem cell field also actively utilizes AI. Artificial intelligence has the potential to make significant advances in disease risk prediction, diagnosis, prognosis, and treatment and to reshape the future of healthcare. This review summarizes the applications and advancements of AI technology in fields such as drug development, regenerative medicine, and stem cell research.
- 26 June 2024
- Published by MDPI AG in Technologies
- Vol. 12 (7) , 95
Open AccessIntegrating Artificial Intelligence to Biomedical Science: New Applications for Innovative Stem Cell Research and Drug Development
Artificial intelligence (AI) is rapidly advancing, aiming to mimic human cognitive abilities, and is addressing complex medical challenges in the field of biological science. Over the past decade, AI has experienced exponential growth and proven its effectiveness in processing massive datasets and optimizing decision-making. The main content of this review paper emphasizes the active utilization of AI in the field of stem cells. Stem cell therapies use diverse stem cells for drug development, disease modeling, and medical treatment research. However, cultivating and differentiating stem cells, along with demonstrating cell efficacy, require significant time and labor. In this review paper, convolutional neural networks (CNNs) are widely used to overcome these limitations by analyzing stem cell images, predicting cell types and differentiation efficiency, and enhancing therapeutic outcomes. In the biomedical sciences field, AI algorithms are used to automatically screen large compound databases, identify potential molecular structures and characteristics, and evaluate the efficacy and safety of candidate drugs for specific diseases. Also, AI aids in predicting disease occurrence by analyzing patients’ genetic data, medical images, and physiological signals, facilitating early diagnosis. The stem cell field also actively utilizes AI. Artificial intelligence has the potential to make significant advances in disease risk prediction, diagnosis, prognosis, and treatment and to reshape the future of healthcare. This review summarizes the applications and advancements of AI technology in fields such as drug development, regenerative medicine, and stem cell research.
- Open Access
- 24 July 2023
- Published by Wiley in Advanced Intelligent Systems
- Vol. 5 (7)
Prediction of Stem Cell State Using Cell Image‐Based Deep Learning
- 24 July 2023
- Published by Wiley in Advanced Intelligent Systems
- Vol. 5 (7)
Open AccessPrediction of Stem Cell State Using Cell Image‐Based Deep Learning
- Open Access
- 10 May 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1)
Current Status of Cardiovascular Disease According to the Duration of Hypertension in Korean Adults
Background: Today, medical technology and healthcare advances have led to an increased life expectancy; however, the prevalence of chronic diseases such as hypertension, diabetes mellitus, stroke, and cardiovascular events is continuously rising. In particular, hypertension is a crucial factor in cardiovascular and cerebrovascular diseases, and it is known that prevention and management are essential. Objectives: This study investigates the prevalence and management of hypertension in Korean adults and evaluates its correlation with the risk of cardiovascular disease (CVD) and stroke. Method: The Korean National Health and Nutritional Examination Survey (KNHANES) database was utilized for this study (https://knhanes.cdc.go.kr). The subjects of this survey were sampled to represent the entire population of Korea. The study aims to assess the risk of CVD and stroke according to the duration of hypertension. We also examined the impact of hypertension control on the risk of CVD and stroke. This study is a retrospective cross-sectional study, so future risks cannot be assessed, but only the disease status at the same time point. Results: A total of 61,379 subjects were enrolled in the KNHANES database, representing Korea’s population of 49,068,178 subjects. The prevalence of hypertension was 25.7% (9,965,618 subjects) of the total population. The prevalence of hypertension increased rapidly with the age of the population. As the duration of hypertension increased, the risks of CVD and stroke also increased. When hypertension lasts longer than 20 years, ischemic heart disease, myocardial infarction, and stroke prevalence were 14.6%, 5.0%, and 12.2%, respectively. However, achieving a target blood pressure (BP) goal below 140/90 mmHg reduced the risk of all CVD and stroke by nearly half. Nevertheless, fewer than two-thirds of patients in Korea with hypertension achieved this targeted blood pressure goal. Conclusions: Our study confirmed that the prevalence of hypertension in Korean adults was higher than a quarter but also showed that the risk of CVD and stroke was significantly reduced by achieving optimal blood pressure control. Based on these results, policy efforts are needed to reach the target BP and improve the treatment rates for hypertension in Korea.
- 10 May 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1)
Open AccessCurrent Status of Cardiovascular Disease According to the Duration of Hypertension in Korean Adults
Background: Today, medical technology and healthcare advances have led to an increased life expectancy; however, the prevalence of chronic diseases such as hypertension, diabetes mellitus, stroke, and cardiovascular events is continuously rising. In particular, hypertension is a crucial factor in cardiovascular and cerebrovascular diseases, and it is known that prevention and management are essential. Objectives: This study investigates the prevalence and management of hypertension in Korean adults and evaluates its correlation with the risk of cardiovascular disease (CVD) and stroke. Method: The Korean National Health and Nutritional Examination Survey (KNHANES) database was utilized for this study (https://knhanes.cdc.go.kr). The subjects of this survey were sampled to represent the entire population of Korea. The study aims to assess the risk of CVD and stroke according to the duration of hypertension. We also examined the impact of hypertension control on the risk of CVD and stroke. This study is a retrospective cross-sectional study, so future risks cannot be assessed, but only the disease status at the same time point. Results: A total of 61,379 subjects were enrolled in the KNHANES database, representing Korea’s population of 49,068,178 subjects. The prevalence of hypertension was 25.7% (9,965,618 subjects) of the total population. The prevalence of hypertension increased rapidly with the age of the population. As the duration of hypertension increased, the risks of CVD and stroke also increased. When hypertension lasts longer than 20 years, ischemic heart disease, myocardial infarction, and stroke prevalence were 14.6%, 5.0%, and 12.2%, respectively. However, achieving a target blood pressure (BP) goal below 140/90 mmHg reduced the risk of all CVD and stroke by nearly half. Nevertheless, fewer than two-thirds of patients in Korea with hypertension achieved this targeted blood pressure goal. Conclusions: Our study confirmed that the prevalence of hypertension in Korean adults was higher than a quarter but also showed that the risk of CVD and stroke was significantly reduced by achieving optimal blood pressure control. Based on these results, policy efforts are needed to reach the target BP and improve the treatment rates for hypertension in Korea.
- Open Access
- 17 April 2023
- Published by Wiley in Advanced Intelligent Systems
- Vol. 5 (7)
Prediction of Stem Cell State Using Cell Image‐Based Deep Learning
Stem cells represent an ideal source for regenerative medicine; however, longitudinal assessment of stem cell phenotype and function is challenging. Contrastingly, a convolutional neural network (CNN) algorithm can automatically extract the image features and produce highly accurate image recognition. Thus, this study implements CNN to establish stable and reproducible cell culture experiments by predicting a unique morphology of pluripotent stem cell (PSC) lines. Interestingly, the algorithm distinguishes the PSC lines cultured in the different cell culture conditions, such as the presence or absence of small molecules and/or the long‐ or short‐term culture in our induced PSC (iPSC) models, which include iPSC lines with abnormal gene expression patterns and genomic abnormalities. Our deep learning technology accurately classifies the various cell lines with or without genetic defects using only the cell images, without any labeling process. This suggests that the CNN system may simplify the various tasks involving stable cell cultures and their differentiation.
- 17 April 2023
- Published by Wiley in Advanced Intelligent Systems
- Vol. 5 (7)
Open AccessPrediction of Stem Cell State Using Cell Image‐Based Deep Learning
Stem cells represent an ideal source for regenerative medicine; however, longitudinal assessment of stem cell phenotype and function is challenging. Contrastingly, a convolutional neural network (CNN) algorithm can automatically extract the image features and produce highly accurate image recognition. Thus, this study implements CNN to establish stable and reproducible cell culture experiments by predicting a unique morphology of pluripotent stem cell (PSC) lines. Interestingly, the algorithm distinguishes the PSC lines cultured in the different cell culture conditions, such as the presence or absence of small molecules and/or the long‐ or short‐term culture in our induced PSC (iPSC) models, which include iPSC lines with abnormal gene expression patterns and genomic abnormalities. Our deep learning technology accurately classifies the various cell lines with or without genetic defects using only the cell images, without any labeling process. This suggests that the CNN system may simplify the various tasks involving stable cell cultures and their differentiation.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , LB517
Abstract LB517: Exosome enriched GCC2 in tumor draining pulmonary blood plasma as a clinically informative biomarker in patients with surgically resected lung adenocarcinoma
Background: Early diagnosis is associated with a better prognosis, and improved survival rates for lung cancer patients. Exosomes of liquid biopsy is rapidly introduced in clinical practice, providing possibilities to offer accurate information. We previously reported that tumor draining pulmonary vein blood (TDVP) derived exosomes were increased than the periphery, and GRIP and coiled-coil domain containing 2 (GCC2) in exosomes act as potential lung adenocarcinoma biomarkers. The purpose of this study to evaluate the diagnostic value of exosome enriched GCC2 in peripheral blood and TDPV in patients with lung cancer who underwent surgery. Methods: The utilization of exosome GCC2 in the TDPV of lung cancer for clinically informative diagnosis was investigated using rabbit lung cancer model, healthy control rabbits, patients with surgically resected lung adenocarcinoma, and healthy controls. Exosome GCC2 levels were measured using an enzyme-linked immunosorbent assay (ELISA) and receiver operating characteristic curves were used to calculate the diagnostic efficiency of carcinoembryonic antigen (CEA), exosome CD63, plasma GCC2, and exosome GCC2. Results: In the rabbit lung cancer model, the expression of exosome GCC2 from the TDPV significantly increased compared with that in the periphery, as determined by western blotting. Of the 70 patients included in the study, and the mean age of all patients was 65.8 ± 9.0 years. The AUC values of CEA according to the blood sampling sites were not significant (all p > 0.05). By contrast, the AUC values of CD63 were 80.0% for TDPV (p < 0.0001) and 55.0% for the periphery (p = 0.42), respectively. The AUC values of plasma GCC2 in the periphery and TDPV were 68.0% (p > 0.05) and 74.0% (p < 0.0001), respectively. Importantly, the diagnostic accuracy values of exosome GCC2 in the periphery and TDPV were 81.0% (p < 0.0001) and 90.0% (p < 0.0001), respectively. The increasing trend of exosome GCC2 in the TDPV had a significantly higher correlation with pathological stages than that of the periphery (periphery, p < 0.05; TDPV, p < 0.0001). Moreover, exosome GCC2 in the TDPV was associated with pathological stage (p < 0.001), lymph node metastasis (p < 0.01), and lymphatic invasion (p < 0.05). Conclusion: Exosome enriched GCC2 in the TDPV was significantly correlated with pathological stages and accurate AUL value than that in the periphery. Exosome GCC2 in TDPV may be a promising and clinically informative biomarker for patients with lung cancer who have undergone surgery. Citation Format: Byeong Hyeon Choi, Yu Hua Quan, Jiyun Rho, Kyungsu Kim, Jun Hee Lee, Yeonho Choi, Yong Park, Ji-Ho Park, Sunghoi Hong, Hyun Koo Kim. Exosome enriched GCC2 in tumor draining pulmonary blood plasma as a clinically informative biomarker in patients with surgically resected lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB517.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , LB517
Open AccessAbstract LB517: Exosome enriched GCC2 in tumor draining pulmonary blood plasma as a clinically informative biomarker in patients with surgically resected lung adenocarcinoma
Background: Early diagnosis is associated with a better prognosis, and improved survival rates for lung cancer patients. Exosomes of liquid biopsy is rapidly introduced in clinical practice, providing possibilities to offer accurate information. We previously reported that tumor draining pulmonary vein blood (TDVP) derived exosomes were increased than the periphery, and GRIP and coiled-coil domain containing 2 (GCC2) in exosomes act as potential lung adenocarcinoma biomarkers. The purpose of this study to evaluate the diagnostic value of exosome enriched GCC2 in peripheral blood and TDPV in patients with lung cancer who underwent surgery. Methods: The utilization of exosome GCC2 in the TDPV of lung cancer for clinically informative diagnosis was investigated using rabbit lung cancer model, healthy control rabbits, patients with surgically resected lung adenocarcinoma, and healthy controls. Exosome GCC2 levels were measured using an enzyme-linked immunosorbent assay (ELISA) and receiver operating characteristic curves were used to calculate the diagnostic efficiency of carcinoembryonic antigen (CEA), exosome CD63, plasma GCC2, and exosome GCC2. Results: In the rabbit lung cancer model, the expression of exosome GCC2 from the TDPV significantly increased compared with that in the periphery, as determined by western blotting. Of the 70 patients included in the study, and the mean age of all patients was 65.8 ± 9.0 years. The AUC values of CEA according to the blood sampling sites were not significant (all p > 0.05). By contrast, the AUC values of CD63 were 80.0% for TDPV (p < 0.0001) and 55.0% for the periphery (p = 0.42), respectively. The AUC values of plasma GCC2 in the periphery and TDPV were 68.0% (p > 0.05) and 74.0% (p < 0.0001), respectively. Importantly, the diagnostic accuracy values of exosome GCC2 in the periphery and TDPV were 81.0% (p < 0.0001) and 90.0% (p < 0.0001), respectively. The increasing trend of exosome GCC2 in the TDPV had a significantly higher correlation with pathological stages than that of the periphery (periphery, p < 0.05; TDPV, p < 0.0001). Moreover, exosome GCC2 in the TDPV was associated with pathological stage (p < 0.001), lymph node metastasis (p < 0.01), and lymphatic invasion (p < 0.05). Conclusion: Exosome enriched GCC2 in the TDPV was significantly correlated with pathological stages and accurate AUL value than that in the periphery. Exosome GCC2 in TDPV may be a promising and clinically informative biomarker for patients with lung cancer who have undergone surgery. Citation Format: Byeong Hyeon Choi, Yu Hua Quan, Jiyun Rho, Kyungsu Kim, Jun Hee Lee, Yeonho Choi, Yong Park, Ji-Ho Park, Sunghoi Hong, Hyun Koo Kim. Exosome enriched GCC2 in tumor draining pulmonary blood plasma as a clinically informative biomarker in patients with surgically resected lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB517.
- Open Access
- 13 January 2022
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 7 (1) , 1-15
OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease
The generation of human oligodendrocyte progenitor cells (OPCs) may be therapeutically valuable for human demyelinating diseases such as multiple sclerosis. Here, we report the direct reprogramming of human somatic cells into expandable induced OPCs (iOPCs) using a combination of OCT4 and a small molecule cocktail. This method enables generation of A2B5+(an early marker for OPCs) iOPCs within 2 weeks retaining the ability to differentiate into MBP-positive mature oligodendrocytes. RNA-seq analysis revealed that the transcriptome of O4+iOPCs was similar to that of O4+OPCs and ChIP-seq analysis revealed that putative OCT4-binding regions were detected in the regulatory elements of CNS development-related genes. Notably, engrafted iOPCs remyelinated the brains of adult shiverer mice and experimental autoimmune encephalomyelitis mice with MOG-induced 14 weeks after transplantation. In conclusion, our study may contribute to the development of therapeutic approaches for neurological disorders, as well as facilitate the understanding of the molecular mechanisms underlying glial development.
- 13 January 2022
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 7 (1) , 1-15
Open AccessOCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease
The generation of human oligodendrocyte progenitor cells (OPCs) may be therapeutically valuable for human demyelinating diseases such as multiple sclerosis. Here, we report the direct reprogramming of human somatic cells into expandable induced OPCs (iOPCs) using a combination of OCT4 and a small molecule cocktail. This method enables generation of A2B5+(an early marker for OPCs) iOPCs within 2 weeks retaining the ability to differentiate into MBP-positive mature oligodendrocytes. RNA-seq analysis revealed that the transcriptome of O4+iOPCs was similar to that of O4+OPCs and ChIP-seq analysis revealed that putative OCT4-binding regions were detected in the regulatory elements of CNS development-related genes. Notably, engrafted iOPCs remyelinated the brains of adult shiverer mice and experimental autoimmune encephalomyelitis mice with MOG-induced 14 weeks after transplantation. In conclusion, our study may contribute to the development of therapeutic approaches for neurological disorders, as well as facilitate the understanding of the molecular mechanisms underlying glial development.
- Open Access
GCC2 as a New Early Diagnostic Biomarker for Non-Small Cell Lung Cancer
No specific markers have been identified to detect non-small cell lung cancer (NSCLC) cell-derived exosomes circulating in the blood. Here, we report a new biomarker that distinguishes between cancer and non-cancer cell-derived exosomes. Exosomes isolated from patient plasmas at various pathological stages of NSCLC, NSCLC cell lines, and human pulmonary alveolar epithelial cells isolated using size exclusion chromatography were characterized. The GRIP and coiled-coil domain-containing 2 (GCC2) protein, involved in endosome-to-Golgi transport, was identified by proteomics analysis of NSCLC cell line-derived exosomes. GCC2 protein levels in the exosomes derived from early-stage NSCLC patients were higher than those from healthy controls. Receiver operating characteristic curve analysis revealed the diagnostic sensitivity and specificity of exosomal GCC2 to be 90% and 75%, respectively. A high area under the curve, 0.844, confirmed that GCC2 levels could effectively distinguish between the exosomes. These results demonstrate GCC2 as a promising early diagnostic biomarker for NSCLC.
Open AccessGCC2 as a New Early Diagnostic Biomarker for Non-Small Cell Lung Cancer
No specific markers have been identified to detect non-small cell lung cancer (NSCLC) cell-derived exosomes circulating in the blood. Here, we report a new biomarker that distinguishes between cancer and non-cancer cell-derived exosomes. Exosomes isolated from patient plasmas at various pathological stages of NSCLC, NSCLC cell lines, and human pulmonary alveolar epithelial cells isolated using size exclusion chromatography were characterized. The GRIP and coiled-coil domain-containing 2 (GCC2) protein, involved in endosome-to-Golgi transport, was identified by proteomics analysis of NSCLC cell line-derived exosomes. GCC2 protein levels in the exosomes derived from early-stage NSCLC patients were higher than those from healthy controls. Receiver operating characteristic curve analysis revealed the diagnostic sensitivity and specificity of exosomal GCC2 to be 90% and 75%, respectively. A high area under the curve, 0.844, confirmed that GCC2 levels could effectively distinguish between the exosomes. These results demonstrate GCC2 as a promising early diagnostic biomarker for NSCLC.